Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SOC) Clear all
Terminated Phase 3 Interventional

A Study With Imlifidase in Anti-GBM Disease

NCT05679401
View directory record Official record
Conditions
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions
Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
Interventions
STK-012, pembrolizumab KEYTRUDA®, pemetrexed, carboplatin
Drug
Lead sponsor
Synthekine
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
33
States / cities
Tucson, Arizona • Beverly Hills, California • Fullerton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Early Phase 1 Interventional

Bacterial Intestinal Gut Modification Around Cancer Surgery (BIG MACS) Diet

NCT05658263
View directory record Official record
Conditions
Dysbiosis, Sarcopenia, Colon Cancer
Interventions
Standard Diet, BIG MACS Diet
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated No phase listed Observational

Sinus Augmentation With Dental Implant

NCT00991393
View directory record Official record
Conditions
Maxillary Sinus Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Fullerton, California • Denver, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated Phase 2 Interventional Results available

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

NCT03339401
View directory record Official record
Conditions
Adenovirus
Interventions
Standard of Care, Brincidofovir
Other · Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 3 Interventional

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BNT324, Docetaxel, Prednisone/prednisolone
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
21
States / cities
Santa Barbara, California • Aurora, Colorado • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 2 Interventional Results available

The Fibrin Pad Cardiovascular Study

NCT01681030
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
EVARREST™, Topical hemostat, Standard of Care
Biological · Other
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Standard of Care, JCAR017
Drug · Genetic
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
28
States / cities
Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated Not applicable Interventional

The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction

NCT05028101
View directory record Official record
Conditions
Breast Reconstruction
Interventions
Delayed autologous breast reconstruction, Perioperative Functional Medicine (FM) Care
Procedure · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 17, 2026, 4:41 AM EDT
Not listed Not applicable Interventional

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

NCT05413395
View directory record Official record
Conditions
Eczema
Interventions
topical colloidal oatmeal formulation with a modified plant oil, topical colloidal oatmeal formulation
Other
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated Phase 1 Interventional

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

NCT04948554
View directory record Official record
Conditions
Systemic Sclerosis With and Without Interstitial Lung Disease
Interventions
MK-2225, Placebo
Biological
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

NCT05541822
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Vabametkib, Lazertinib
Drug
Lead sponsor
Abion Inc
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
View directory record Official record
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670
View directory record Official record
Conditions
Prostate Cancer
Interventions
Investigators choice of SoC, AAA817
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

NCT05424354
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Altrazeal (R) Transforming Powder Dressing, Standard of Care burn dressing
Device · Other
Lead sponsor
ULURU Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Terminated Phase 3 Interventional Results available

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NVAMD Satellite Study

NCT02251366
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Physician-guided diagnostic
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting No phase listed Observational

A Study of Paramedic HF Management

NCT06874556
View directory record Official record
Conditions
Heart Failure
Interventions
CP-HF Management
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
Drug · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 4:41 AM EDT
Recruiting Phase 2 Interventional

Spray Cryotherapy for the Management of Benign Central Airway Stenosis (Cryo-BAS)

NCT06761170
View directory record Official record
Conditions
Stenosis of Trachea
Interventions
Spray cryo therapy, Standard of Care (SOC)
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 17, 2026, 4:41 AM EDT
Completed Not applicable Interventional

Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer

NCT02887235
View directory record Official record
Conditions
Quality of Life
Interventions
Home Delivered, Medically Tailored Meals (HDTM)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 17, 2026, 4:41 AM EDT